This is a mechanism module, not a specific disease. It models the compartment-specific, direction-specific pharmacology characterized by the Streicher lab across a coherent series of mouse studies (PMID:32371496, PMID:37040443, PMID:41031962, PMID:42263270, PMID:38926482). The flagship paper for this module is Bowden et al. 2026 (PMID:41031962, DOI:10.1097/j.pain.0000000000003813), which established the microglial Src arm.
CRITICAL SCOPE CAVEAT (compartment- and context-specificity). The enhancement is specific to the SPINAL CORD. Hsp90 regulates downstream opioid signaling OPPOSITELY in the brain versus the spinal cord: brain or systemic non-selective Hsp90 inhibition BLOCKS opioid antinociception (PMID:42263270, PMID:32701840), and in chemotherapy-induced peripheral neuropathy and cancer-induced bone pain models Hsp90 inhibitors reduced or blocked opioid antinociception (PMID:32701840). The translationally feasible route is therefore selective inhibition of the spinal-cord-active isoforms (Hsp90-beta, Grp94), not non-selective/systemic Hsp90 blockade (PMID:38926482). Do not let a conforming entry overstate this as a generic "Hsp90 inhibition relieves pain" claim.
All evidence is MODEL_ORGANISM (mouse, intrathecal/intracerebroventricular dosing, CRISPR knockdown); the strategy is preclinical. Conforming disorder nodes should substitute the pain-context-specific model but keep the evidence_source as MODEL_ORGANISM until human data exist.
Node term-binding follows module convention (GO/CL terms only; the drug identity CHEBI id lives on the treatment therapeutic_agent). Key conformance / treatment-relevant target: the trigger node "Spinal Hsp90 Chaperone Restraint of MOR Signaling" is where the drug acts (treatment target_mechanisms INHIBITS the restraint); the central effector "ERK-RSK Cascade Activation" is the convergent hub every mechanistic arm (microglial Src and CGRP-neuron PKCbeta) funnels through.
Can spinal-cord-restricted Hsp90 inhibition (selective Hsp90-beta or Grp94 inhibitors delivered systemically) reproduce in humans the opioid dose-reduction and tolerance-rescue seen in mice, without triggering the brain/systemic Hsp90-inhibition effect that blocks opioid antinociception?
KNOWLEDGE GAP
OPEN
gap_hsp90_spinal_translational_selectivity
Attached to:
Spinal Hsp90 Chaperone Restraint of MOR Signaling
Increased Opioid Antinociception and Improved Therapeutic Index
The entire module chain is established in mice with intrathecal or isoform-selective dosing. Because non-selective/systemic Hsp90 inhibition has the opposite (opioid-blocking) effect in the brain and in some cancer-pain models, clinical translation depends on achieving spinal-compartment or spinal-isoform selectivity in humans, which has not yet been demonstrated.
Spinal Hsp90 Chaperone Restraint of MOR Signaling
trigger
The trigger and the drug-target node, named for the biological process that the treatment acts on (following module convention). In the spinal dorsal horn the chaperone Hsp90 normally restrains a downstream mu-opioid receptor (MOR) signaling cascade. Pharmacological Hsp90 inhibition delivered intrathecally (17-AAG/tanespimycin, KU-32) removes this chaperone-imposed brake, enabling the amplified MOR signaling modeled by the downstream nodes. The effect is compartment-specific: inhibiting Hsp90 specifically in the spinal cord enhances opioid antinociception, whereas brain or systemic non-selective inhibition has the opposite, opioid-blocking effect.
Downstream
-
Microglial Src Kinase Activation
-
PKCbeta Activation in CGRP Neurons
Microglial Src Kinase Activation
amplifier
The amplifier arm characterized by the flagship study. Following spinal Hsp90 inhibition, Src-family kinase is upregulated and activated in the spinal dorsal horn, where activated Src colocalizes with microglia. Microglial Src is causally required: microglial-specific Src CRISPR knockdown abolishes the enhanced antinociception, and pharmacological microglial inhibition (minocycline/PLX3397) mimics the Hsp90-inhibition effect while microglial activation (LPS) reverses it. Src acts upstream of ERK in this cascade.
Downstream
-
ERK-RSK Cascade Activation
PKCbeta Activation in CGRP Neurons
amplifier
A second, parallel amplifier arm established by the same lab with the same cell-type-selective CRISPR logic as the microglial Src arm. Spinal Hsp90 inhibition (with opioid) selectively activates protein kinase C beta (PKCbeta) in calcitonin-gene-related-peptide (CGRP) primary-afferent neurons of the dorsal horn; PKCbeta in these specific cells is required for the enhanced opioid antinociception. Like the Src arm, this contributes to the convergent ERK/downstream MOR signaling enhancement, and it was demonstrated in tail-flick and postsurgical (paw-incision) pain models.
Downstream
-
ERK-RSK Cascade Activation
ERK-RSK Cascade Activation
central effector
The central effector and convergent hub. Spinal Hsp90 inhibition permits opioid-induced phosphorylation of ERK1/2 and increased abundance of the kinase RSK in the spinal dorsal horn. Mechanistically this convergence is gated by relief of an opioid-induced, AMPK-mediated negative feedback loop (Hsp90 inhibition lowers spinal AMPK, disabling the brake), and microglial Src acts upstream of ERK. Blocking ERK, RSK, or protein synthesis abolishes the enhancement, marking this cascade as the rate-limiting step every mechanistic arm funnels through.
Downstream
-
Enhanced Spinal Mu-Opioid Receptor Antinociceptive Signaling
Enhanced Spinal Mu-Opioid Receptor Antinociceptive Signaling
effector
The effector node. The relieved, amplified cascade downstream of the spinal mu-opioid receptor increases antinociceptive output while the Hsp90-restrained pronociceptive arm is disabled. This enhanced MOR signaling is localized to the spinal cord and is the disorder-agnostic convergence point that translates the molecular cascade into increased analgesic efficacy.
Downstream
-
Increased Opioid Antinociception and Improved Therapeutic Index
Increased Opioid Antinociception and Improved Therapeutic Index
consequence
The consequence node. The enhanced spinal MOR signaling produces increased opioid antinociception at the behavioral level, boosting analgesic potency while reducing and rescuing tolerance and leaving reward and constipation liability largely unchanged, i.e. an improved therapeutic index and an opioid dose-reduction opportunity. Conforming pain-disorder entries substitute the pain-context-specific behavioral model (thermal/tail-flick, incisional/postsurgical, neuropathic, cancer pain).